Asset
IBREXAFUNGERP
Revenue
No revenue reported in loaded filings.
Clinical trials (13)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05178862 | phase3 | terminated | 2022-08-03 | 2025-11-07 | Scynexis, Inc. | A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole |
| NCT05668429 | phase1 | completed | 2022-12-14 | 2023-01-28 | Scynexis, Inc. | ADME Study of [14^C]-Ibrexafungerp in Healthy Male Subjects |
| NCT03253094 | phase2 | completed | 2017-08-01 | 2018-05-04 | Scynexis, Inc. | Dose-Finding Study of Oral Ibrexafungep (SCY-078) vs. Oral Fluconazole in Subjects With Acute Vulvovaginal Candidiasis |
| NCT03987620 | phase3 | completed | 2019-06-07 | 2020-03-29 | Scynexis, Inc. | Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis |
| NCT03734991 | phase3 | completed | 2019-01-04 | 2019-08-21 | Scynexis, Inc. | Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis (VANISH 303) |
FDA applications (0)
This company has no applications containing this asset.